Complete financial analysis of Crystalvue Medical Corporation (6527.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Crystalvue Medical Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Gale Pacific Limited (GAP.AX) Income Statement Analysis – Financial Results
- Senvest Capital Inc. (SEC.TO) Income Statement Analysis – Financial Results
- Kiniksa Pharmaceuticals, Ltd. (KNSA) Income Statement Analysis – Financial Results
- Danske Invest Nye Markeder Akk (DKINMAKK.CO) Income Statement Analysis – Financial Results
- Norcros plc (NXR.L) Income Statement Analysis – Financial Results
Crystalvue Medical Corporation (6527.TWO)
About Crystalvue Medical Corporation
Crystalvue Medical Corporation designs, manufactures, and sells ophthalmic medical equipment worldwide. The company offers retinal cameras, tonometers, lens edgers, and gastroenterology supplies. Crystalvue Medical Corporation was founded in 2009 and is based in Taoyuan City, Taiwan.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 823.96M | 795.46M | 721.61M | 504.37M | 661.11M |
Cost of Revenue | 557.22M | 533.71M | 510.22M | 338.98M | 428.54M |
Gross Profit | 266.75M | 261.74M | 211.39M | 165.39M | 232.57M |
Gross Profit Ratio | 32.37% | 32.90% | 29.29% | 32.79% | 35.18% |
Research & Development | 44.67M | 46.97M | 49.20M | 41.28M | 42.83M |
General & Administrative | 70.10M | 55.28M | 47.19M | 44.07M | 0.00 |
Selling & Marketing | 34.29M | 34.69M | 26.55M | 22.39M | 0.00 |
SG&A | 104.40M | 89.97M | 73.73M | 66.45M | 75.67M |
Other Expenses | 0.00 | 18.16M | 20.81M | 4.78M | 0.00 |
Operating Expenses | 142.59M | 136.94M | 122.93M | 107.73M | 118.49M |
Cost & Expenses | 706.29M | 670.65M | 633.15M | 446.72M | 547.03M |
Interest Income | 1.47M | 474.00K | 1.06M | 1.89M | 2.77M |
Interest Expense | 818.00K | 998.00K | 1.17M | 1.34M | 1.51M |
Depreciation & Amortization | 29.17M | 26.15M | 40.88M | 25.40M | 20.07M |
EBITDA | 149.73M | 169.59M | 151.23M | 89.73M | 133.34M |
EBITDA Ratio | 18.17% | 21.32% | 20.96% | 17.79% | 20.17% |
Operating Income | 117.68M | 143.44M | 110.34M | 64.31M | 114.07M |
Operating Income Ratio | 14.28% | 18.03% | 15.29% | 12.75% | 17.25% |
Total Other Income/Expenses | 2.06M | -998.00K | 20.70M | -1.32M | -2.31M |
Income Before Tax | 119.74M | 142.44M | 109.17M | 62.97M | 111.77M |
Income Before Tax Ratio | 14.53% | 17.91% | 15.13% | 12.48% | 16.91% |
Income Tax Expense | 16.34M | 27.41M | 31.93M | 6.35M | 20.66M |
Net Income | 103.40M | 115.03M | 77.24M | 56.62M | 91.08M |
Net Income Ratio | 12.55% | 14.46% | 10.70% | 11.23% | 13.78% |
EPS | 4.13 | 4.59 | 3.09 | 2.23 | 4.06 |
EPS Diluted | 4.09 | 4.51 | 3.05 | 2.21 | 4.02 |
Weighted Avg Shares Out | 25.04M | 25.05M | 25.06M | 25.37M | 22.43M |
Weighted Avg Shares Out (Dil) | 25.28M | 25.51M | 25.37M | 25.63M | 22.68M |
Source: https://incomestatements.info
Category: Stock Reports